Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory M Lucas

Showing results (161-170 of 174) with videos related to

Pageof 18
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2011
HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite studyFrederick L Altice, R Douglas Bruce, Gregory M Lucas, et al.
The Lancet. HIV|April 7, 2019
Integrated HIV testing, prevention, and treatment intervention for key populations in India: a cluster-randomised trialSunil S Solomon, Suniti Solomon, Allison M McFall, et al.
Journal of Hepatology|June 30, 2026
A precision randomized trial of hepatitis C treatment support among people who inject drugs in India: The STOP-C TrialSunil S Solomon, Aylur K Srikrishnan, Allison M McFall, et al.
Journal of Hepatology|October 12, 2019
Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs: A cluster-randomized trialSunil Suhas Solomon, Thomas C Quinn, Suniti Solomon, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 8, 2015
Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058David S Metzger, Deborah Donnell, David D Celentano, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 7, 2022
Effect of Adopting the New Race-Free 2021 Chronic Kidney Disease Epidemiology Collaboration Estimated Glomerular Filtration Rate Creatinine Equation on Racial Differences in Kidney Disease Progression Among People With Human Immunodeficiency Virus: An Observational StudyAnthony N Muiru, Erin Madden, Rebecca Scherzer, et al.
Addiction (Abingdon, England)|February 7, 2022
HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trialP Todd Korthuis, Ryan R Cook, Paula J Lum, et al.
AIDS Research and Treatment|March 20, 2015
Ascertainment and verification of end-stage renal disease and end-stage liver disease in the north american AIDS cohort collaboration on research and designMari M Kitahata, Daniel R Drozd, Heidi M Crane, et al.
BMJ Medicine|May 21, 2025
Statins for primary prevention of cardiovascular events in people with HIV: target trial and modelling studyHenock G Yebyo, Huldrych F Guenthard, Eva A Rehfuess, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 20, 2014
End-stage renal disease among HIV-infected adults in North AmericaAlison G Abraham, Keri N Althoff, Yuezhou Jing, et al.
Pageof 18

Showing results (161-170 of 174) with videos related to

Sort By:
Pageof 18
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2011
HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite studyFrederick L Altice, R Douglas Bruce, Gregory M Lucas, et al.
The Lancet. HIV|April 7, 2019
Integrated HIV testing, prevention, and treatment intervention for key populations in India: a cluster-randomised trialSunil S Solomon, Suniti Solomon, Allison M McFall, et al.
Journal of Hepatology|June 30, 2026
A precision randomized trial of hepatitis C treatment support among people who inject drugs in India: The STOP-C TrialSunil S Solomon, Aylur K Srikrishnan, Allison M McFall, et al.
Journal of Hepatology|October 12, 2019
Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs: A cluster-randomized trialSunil Suhas Solomon, Thomas C Quinn, Suniti Solomon, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 8, 2015
Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058David S Metzger, Deborah Donnell, David D Celentano, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 7, 2022
Effect of Adopting the New Race-Free 2021 Chronic Kidney Disease Epidemiology Collaboration Estimated Glomerular Filtration Rate Creatinine Equation on Racial Differences in Kidney Disease Progression Among People With Human Immunodeficiency Virus: An Observational StudyAnthony N Muiru, Erin Madden, Rebecca Scherzer, et al.
Addiction (Abingdon, England)|February 7, 2022
HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trialP Todd Korthuis, Ryan R Cook, Paula J Lum, et al.
AIDS Research and Treatment|March 20, 2015
Ascertainment and verification of end-stage renal disease and end-stage liver disease in the north american AIDS cohort collaboration on research and designMari M Kitahata, Daniel R Drozd, Heidi M Crane, et al.
BMJ Medicine|May 21, 2025
Statins for primary prevention of cardiovascular events in people with HIV: target trial and modelling studyHenock G Yebyo, Huldrych F Guenthard, Eva A Rehfuess, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 20, 2014
End-stage renal disease among HIV-infected adults in North AmericaAlison G Abraham, Keri N Althoff, Yuezhou Jing, et al.
Pageof 18